Prostate cancer gene therapy

F. A. Ferrer, Ronald Rodriguez

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Cancer-specific gene therapy is still in its infancy. Although the first gene therapy trials were initiated in the late 1980s, it was only more recently that the first successful treatment of a genetic disease was reported. The current problems with low efficiency of gene transfer coupled with the immunologic difficulties with certain vectors indicate that more effort needs to be directed at the basic science of gene transfer. Ultimately, successful camcer-specific gene therapy will require combinations of the lessons learned from the ex vivo and in vivo paradigms. The next generation of gene therapy trials likely will focus on combination therapy with conventional chemotherapeutic agents, differentiating agents, or radiation theraphy. The obstacle to the development of gene-based human therapeutic (i.e., molecular medicine) are formidable, but the benefits are so great that eventually the technical issues of gene transfer methodology will be worked out, and ultimately this will become the standard of care, not only for inborn errors of metabolism, but also for cancer.

Original languageEnglish (US)
Pages (from-to)497-508
Number of pages12
JournalHematology/Oncology Clinics of North America
Volume15
Issue number3
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Neoplasm Genes
Genetic Therapy
Prostatic Neoplasms
Genes
Molecular Medicine
Inborn Errors Metabolism
Inborn Genetic Diseases
Standard of Care
Therapeutics
Radiation
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Prostate cancer gene therapy. / Ferrer, F. A.; Rodriguez, Ronald.

In: Hematology/Oncology Clinics of North America, Vol. 15, No. 3, 2001, p. 497-508.

Research output: Contribution to journalArticle

@article{1e2f4256ad0440509c5ffa6c04274033,
title = "Prostate cancer gene therapy",
abstract = "Cancer-specific gene therapy is still in its infancy. Although the first gene therapy trials were initiated in the late 1980s, it was only more recently that the first successful treatment of a genetic disease was reported. The current problems with low efficiency of gene transfer coupled with the immunologic difficulties with certain vectors indicate that more effort needs to be directed at the basic science of gene transfer. Ultimately, successful camcer-specific gene therapy will require combinations of the lessons learned from the ex vivo and in vivo paradigms. The next generation of gene therapy trials likely will focus on combination therapy with conventional chemotherapeutic agents, differentiating agents, or radiation theraphy. The obstacle to the development of gene-based human therapeutic (i.e., molecular medicine) are formidable, but the benefits are so great that eventually the technical issues of gene transfer methodology will be worked out, and ultimately this will become the standard of care, not only for inborn errors of metabolism, but also for cancer.",
author = "Ferrer, {F. A.} and Ronald Rodriguez",
year = "2001",
doi = "10.1016/S0889-8588(05)70228-8",
language = "English (US)",
volume = "15",
pages = "497--508",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Prostate cancer gene therapy

AU - Ferrer, F. A.

AU - Rodriguez, Ronald

PY - 2001

Y1 - 2001

N2 - Cancer-specific gene therapy is still in its infancy. Although the first gene therapy trials were initiated in the late 1980s, it was only more recently that the first successful treatment of a genetic disease was reported. The current problems with low efficiency of gene transfer coupled with the immunologic difficulties with certain vectors indicate that more effort needs to be directed at the basic science of gene transfer. Ultimately, successful camcer-specific gene therapy will require combinations of the lessons learned from the ex vivo and in vivo paradigms. The next generation of gene therapy trials likely will focus on combination therapy with conventional chemotherapeutic agents, differentiating agents, or radiation theraphy. The obstacle to the development of gene-based human therapeutic (i.e., molecular medicine) are formidable, but the benefits are so great that eventually the technical issues of gene transfer methodology will be worked out, and ultimately this will become the standard of care, not only for inborn errors of metabolism, but also for cancer.

AB - Cancer-specific gene therapy is still in its infancy. Although the first gene therapy trials were initiated in the late 1980s, it was only more recently that the first successful treatment of a genetic disease was reported. The current problems with low efficiency of gene transfer coupled with the immunologic difficulties with certain vectors indicate that more effort needs to be directed at the basic science of gene transfer. Ultimately, successful camcer-specific gene therapy will require combinations of the lessons learned from the ex vivo and in vivo paradigms. The next generation of gene therapy trials likely will focus on combination therapy with conventional chemotherapeutic agents, differentiating agents, or radiation theraphy. The obstacle to the development of gene-based human therapeutic (i.e., molecular medicine) are formidable, but the benefits are so great that eventually the technical issues of gene transfer methodology will be worked out, and ultimately this will become the standard of care, not only for inborn errors of metabolism, but also for cancer.

UR - http://www.scopus.com/inward/record.url?scp=0034889084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034889084&partnerID=8YFLogxK

U2 - 10.1016/S0889-8588(05)70228-8

DO - 10.1016/S0889-8588(05)70228-8

M3 - Article

C2 - 11525293

AN - SCOPUS:0034889084

VL - 15

SP - 497

EP - 508

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 3

ER -